The MPS I Registry program, sponsored and administered by Genzyme Corporation, is a worldwide database that tracks health-related information for people with MPS I, allowing doctors and health care professionals to better understand and treat the disorder.
“With patients and their families, I continue learning over and over what are the important things in life and which are the ones that are worthy to fight for: life, dignity and hope.”– Dr. Muñoz, MD
: A A A
Email this page Print this Page
MPS I is seen in all populations at a frequency of approximately 1:100,000. There are severe and attenuated forms, (historically known as Hurler, Hurler-Scheie, and Scheie) that occur in roughly equal proportions.
When a child or young adult presents with joint pain and stiffness but does not demonstrate morning stiffness or local inflammation around the affected joints, MPS I should be considered part of a differential diagnostic process along with Juvenile Idiopathic Arthritis .
Alicia is a 16-year-old with MPS I who was diagnosed 10 years ago. Watch Alicia’s story to find out how she is handling life as a teenager living with MPS I.
More information by specialty:
In patients with moderate to severe MPS I, coarse facial features develop slowly in the first year and by two years of age are usually fairly obvious.
One of the world's leading biotechnology companies, Genzyme is dedicated to making a major positive impact on the lives of people with serious diseases. Learn More
500 Kendall Street
Cambridge, MA 02142
Genzyme Europe BV
1411 DD Naarden
+ 31 35 699 1200